# Cenvacibart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cenvacibart

> The next catalyst for cenvacibart, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Feb to May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | cenvacibart |
| Codes | REGN7508 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Cancer-Associated Thrombosis (CAT)](https://sec-api.dev/indications/cancer-associated-thrombosis-cat), [Venous Thromboembolism (VTE)](https://sec-api.dev/indications/venous-thromboembolism-vte), [Atrial Fibrillation (AF)](https://sec-api.dev/indications/atrial-fibrillation-af), [Secondary Stroke](https://sec-api.dev/indications/secondary-stroke), [Peripheral Artery Disease (PAD)](https://sec-api.dev/indications/peripheral-artery-disease-pad), [Symptomatic Venous Thromboembolism (VTE)](https://sec-api.dev/indications/symptomatic-venous-thromboembolism-vte) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07015905 (REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-20 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07015905

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07175428 (Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07175428

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07175428 (Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07175428

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07015905 (REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-20 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07015905

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Symptomatic Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07213778 (REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07213778

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Symptomatic Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07213778 (REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07213778

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07430956 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07430956

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07430956 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07430956

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07697599 (Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-25 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07697599

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Venous Thromboembolism (VTE).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07697599 (Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-25 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07697599

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Peripheral Artery Disease (PAD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07318610 (Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07318610

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Peripheral Artery Disease (PAD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07318610 (Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07318610

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07626411 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07626411

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atrial Fibrillation (AF).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07626411 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07626411

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Secondary Stroke.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07876492 (A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-12-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07876492

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Secondary Stroke.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07876492 (A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-12-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07876492

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cancer-Associated Thrombosis (CAT).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07410117 (REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-23 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07410117

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cancer-Associated Thrombosis (CAT).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07410117 (REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-23 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07410117

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cenvacibart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cenvacibart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cenvacibart

```bibtex
@misc{secapidev_pdufa_cenvacibart_20261116,
  title        = {Cenvacibart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cenvacibart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cenvacibart_20261116","title":"Cenvacibart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cenvacibart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
